The Cooper Companies, Inc. operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia. It also provides range of products and services focusing on women's health, including medical devices, fertility, genomics, and diagnostics and contraception for hospitals and surgical centers, obstetricians' and gynecologists' (ob/gyns) medical offices, and fertility clinics. In addition, the company offers carrier screening, preimplantation genetic screening, and preimplantation genetic diagnosis used in IVF process; IVF medical devices, systems, and equipment; and PARAGARD, a non-hormonal, copper intrauterine device for birth control. Further, The Cooper Companies, Inc. offers its products under Biofinity, clarity 1day, MyDay, and Proclear 1 Day brand name. The company markets its products through a network of field sales representatives, independent agents, and distributors. The Cooper Companies, Inc. was founded in 1980 and is headquartered in Pleasanton, California.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Ophthalmic goods
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNYSE:COO
Previous Symbol
CUSIP21664840
Phone925-460-3600
Debt
Debt-to-Equity Ratio0.70
Current Ratio2.58
Quick Ratio1.54
Price-To-Earnings
Trailing P/E Ratio21.13
Forward P/E Ratio21.02
P/E Growth1.87
Sales & Book Value
Annual Sales$2.53 billion
Price / Sales4.71
Cash Flow$13.6753 per share
Price / Cash Flow17.77
Book Value$64.88 per share
Price / Book3.75
Profitability
EPS (Most Recent Fiscal Year)$11.50
Net Income$372.90 million
Net Margins5.52%
Return on Equity17.86%
Return on Assets9.02%
Miscellaneous
Employees11,800
Outstanding Shares49,140,000
Market Cap$11.94 billion
OptionableOptionable
Cooper Companies (NYSE:COO) Frequently Asked Questions
What is Cooper Companies' stock symbol?
Cooper Companies trades on the New York Stock Exchange (NYSE) under the ticker symbol "COO."
How often does Cooper Companies pay dividends? What is the dividend yield for Cooper Companies?
Cooper Companies announced a semiannual dividend on Friday, July 13th. Stockholders of record on Monday, July 23rd will be paid a dividend of $0.03 per share on Tuesday, August 7th. This represents a dividend yield of 0.02%. The ex-dividend date of this dividend is Friday, July 20th. View Cooper Companies' Dividend History.
How will Cooper Companies' stock buyback program work?
Cooper Companies declared that its board has initiated a stock buyback program on Friday, April 7th 2017, which allows the company to repurchase $500,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to buy up to 5.2% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company's leadership believes its stock is undervalued.
How were Cooper Companies' earnings last quarter?
Cooper Companies Inc (NYSE:COO) announced its quarterly earnings data on Thursday, December, 6th. The medical device company reported $2.87 EPS for the quarter, missing the consensus estimate of $2.96 by $0.09. The medical device company had revenue of $651.50 million for the quarter, compared to the consensus estimate of $645.25 million. Cooper Companies had a net margin of 5.52% and a return on equity of 17.86%. The firm's revenue for the quarter was up 16.0% on a year-over-year basis. During the same period in the prior year, the company earned $2.65 EPS. View Cooper Companies' Earnings History.
When is Cooper Companies' next earnings date?
What guidance has Cooper Companies issued on next quarter's earnings?
Cooper Companies issued an update on its FY19 earnings guidance on Thursday, December, 6th. The company provided earnings per share (EPS) guidance of $11.30-11.70 for the period, compared to the Thomson Reuters consensus EPS estimate of $12.08. The company issued revenue guidance of $2.60-2.66 billion, compared to the consensus revenue estimate of $2.67 billion.Cooper Companies also updated its FY 2019 guidance to $11.30-11.70 EPS.
What price target have analysts set for COO?
9 brokerages have issued 12 month price objectives for Cooper Companies' stock. Their predictions range from $231.00 to $306.00. On average, they expect Cooper Companies' share price to reach $286.8750 in the next year. This suggests a possible upside of 18.1% from the stock's current price. View Analyst Price Targets for Cooper Companies.
What is the consensus analysts' recommendation for Cooper Companies?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cooper Companies in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cooper Companies.
Has Cooper Companies been receiving favorable news coverage?
News stories about COO stock have been trending somewhat positive this week, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cooper Companies earned a coverage optimism score of 0.8 on InfoTrie's scale. They also gave media headlines about the medical device company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term.
Who are some of Cooper Companies' key competitors?
Some companies that are related to Cooper Companies include Illumina (ILMN), HCA Healthcare (HCA), Vertex Pharmaceuticals (VRTX), Zoetis (ZTS), Humana (HUM), Regeneron Pharmaceuticals (REGN), Baxter International (BAX), Edwards Lifesciences (EW), Actelion (ALIOF), ASTELLAS PHARMA/ADR (ALPMY), Centene (CNC), ESSILOR Intl S/S (ESLOY), Takeda Pharmaceutical (TKPYY), Alexion Pharmaceuticals (ALXN) and Eisai (ESALY).
Who are Cooper Companies' key executives?
Cooper Companies' management team includes the folowing people:
- Mr. Albert G. White III, Pres, CEO & Director (Age 48)
- Mr. Daniel G. McBride Esq., Chief Operating Officer, Exec. VP and Pres of CooperVision Inc (Age 54)
- Mr. Agostino Ricupati, Sr. VP of Fin. & Tax and Chief Accounting Officer
- Ms. Carol R. Kaufmann, Advisor (Age 69)
- Mr. Brian Andrews, Sr. VP, CFO & Treasurer
Who are Cooper Companies' major shareholders?
Cooper Companies' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (10.26%), BlackRock Inc. (7.10%), Massachusetts Financial Services Co. MA (5.68%), Janus Henderson Group PLC (5.33%), Frontier Capital Management Co. LLC (1.91%) and FIL Ltd (1.66%). Company insiders that own Cooper Companies stock include A Thomas Bender, Agostino Ricupati, Allan E Rubenstein, Carol R Kaufman, Daniel G Mcbride, Gary S Petersmeyer, Jody S Lindell, Michael Kalkstein, Paul L Remmell, Randal Golden, Robert S Weiss and Stanley Md Zinberg. View Institutional Ownership Trends for Cooper Companies.
Which institutional investors are selling Cooper Companies stock?
COO stock was sold by a variety of institutional investors in the last quarter, including Panagora Asset Management Inc., Massachusetts Financial Services Co. MA, BlackRock Inc., AXA, JPMorgan Chase & Co., JPMorgan Chase & Co., Martingale Asset Management L P and Los Angeles Capital Management & Equity Research Inc.. Company insiders that have sold Cooper Companies company stock in the last year include A Thomas Bender, Agostino Ricupati, Allan E Rubenstein, Carol R Kaufman, Daniel G Mcbride, Gary S Petersmeyer, Michael Kalkstein, Randal Golden, Robert S Weiss and Stanley Md Zinberg. View Insider Buying and Selling for Cooper Companies.
Which institutional investors are buying Cooper Companies stock?
COO stock was bought by a variety of institutional investors in the last quarter, including Findlay Park Partners LLP, Putnam Investments LLC, Morgan Stanley, Marshall Wace North America L.P., Kornitzer Capital Management Inc. KS, FIL Ltd, Frontier Capital Management Co. LLC and Victory Capital Management Inc.. View Insider Buying and Selling for Cooper Companies.
How do I buy shares of Cooper Companies?
Shares of COO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cooper Companies' stock price today?
One share of COO stock can currently be purchased for approximately $243.01.
How big of a company is Cooper Companies?
Cooper Companies has a market capitalization of $11.94 billion and generates $2.53 billion in revenue each year. The medical device company earns $372.90 million in net income (profit) each year or $11.50 on an earnings per share basis. Cooper Companies employs 11,800 workers across the globe.
What is Cooper Companies' official website?
How can I contact Cooper Companies?
Cooper Companies' mailing address is 6140 Stoneridge Mall Road Suite 590, PLEASANTON CA, 94588. The medical device company can be reached via phone at 925-460-3600 or via email at [email protected]
MarketBeat Community Rating for Cooper Companies (NYSE COO)
MarketBeat's community ratings are surveys of what our community members think about Cooper Companies and other stocks. Vote "Outperform" if you believe COO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe COO will underperform the S&P 500 over the long term. You may vote once every thirty days.
